Answering Your Frequently Asked Questions
Prepare for the 7th Genome Editing Therapeutics Summit with this comprehensive FAQ guide covering information on registration, agenda themes, scientific sessions, partnership opportunities and more. This resource is designed to help you navigate the only industry-focused meeting dedicated to translating breakthrough genome editing tools into real-world therapeutic applications.
Can't find what you're looking for? Get in touch at info@hansonwade.com for more information.
General
The 7th Genome Editing Therapeutics Summit, previously known as the CRISPR 2.0 Summit, is an industry-focused meeting designed to support the clinical translation of genome editing therapeutics.
As the only industry meeting dedicated to advancing the application of cutting-edge genome editing tools in therapeutic development, this summit unites R&D, preclinical, translational, regulatory, and C-suite stakeholders around a central objective: maximizing the successful application of genome editing therapies in clinical settings.
Through expert-led sessions, the summit explores:
- Gene editing delivery, including viral vectors and LNP technologies
- In vivo and ex vivo genome editing strategies
- Clinical development, regulatory pathways, and IND progression
- Scalable manufacturing and commercial readiness
The 7th Genome Editing Therapeutics Summit will be held September 28-30 at Hilton Boston Logan Airport.
View our Venue Page for more details.
Event Content
Yes. Unlike broader gene therapy conferences or genomics meetings, the 7th Genome Editing Therapeutics Summit provides a specialized technical forum exclusively focused on CRISPR and next-generation genome editing technologies, offering a much deeper and more specialized agenda.
This meeting is:
- Industry-focused: Dedicated exclusively to therapeutic genome editing
- Translation-driven: Focused on moving CRISPR and gene editing into the clinic
- Solution-oriented: Addressing delivery, safety, scalability, and regulatory hurdles
- Expert-led: Featuring senior leaders from leading biotech and pharma companies
Sessions are tailored to key challenges such as gene editing delivery, in vivo targeting, and clinical translation, ensuring highly relevant and actionable insights for attendees.
Yes. The 7th Genome Editing Therapeutics Summit provides comprehensive coverage of the most critical areas in genome editing drug development, including:
- CRISPR, base editing, and prime editing technologies
- Gene editing delivery systems, including viral vectors and lipid nanoparticles (LNPs)
- Clinical development strategies, from preclinical translation to trial design
- Regulatory considerations and safety, including off-target effects
- Manufacturing and scalability for commercial success
The program brings together experts from leading organizations, who will share real-world insights into advancing genome editing therapeutics from discovery through to clinical application and attendees can expect sessions exploring in vivo and ex vivo delivery approaches, regulatory considerations, clinical trial design, and manufacturing scalability, ensuring a well-rounded understanding of the current landscape and future direction of genome editing.
Yes. In vivo and ex vivo genome editing are core pillars of the agenda, with dedicated sessions exploring:
- Key differences in approach, including advantages and limitations
- Targeting and delivery optimization for specific tissues and indications
- Clinical learnings from programs progressing toward the clinic
- Durability, efficacy, and safety considerations
Through case studies and expert-led discussions, attendees will gain clarity on how to select and optimise the right strategy for their therapeutic goals.
Yes. The 7th Genome Editing Therapeutics Summit includes pre-conference workshops specifically designed to explore genome editing delivery technologies in greater technical depth, with a strong focus on delivery, regulatory strategy, and clinical translation.
Workshop A: Navigating Regulatory IND Packages for Genome Editing Therapeutics
Led by experts from Beam Therapeutics and Eli Lilly, this session explores how to:
- Structure IND submissions for CRISPR and genome editing therapies
- Bridge preclinical and clinical data effectively
- Identify key data required to satisfy regulatory expectations
- Engage with regulators and apply best practices from late-stage programs
Workshop B: Advancing Extrahepatic Delivery for Genome Editing Therapeutics
This workshop focuses on solving one of the field’s biggest challenges: targeted delivery beyond the liver. Join Cytodigm and gain insights on:
- Reducing LNP and AAV liver tropism to improve safety
- Enhancing tissue-specific targeting for in vivo gene editing
- Exploring exosomal delivery and emerging non-viral approaches
- Balancing efficacy, dosing, and regulatory requirements
Yes. The 7th Genome Editing Therapeutics Summit is specifically designed to maximize high-value networking with genome editing and gene therapy experts, bringing together a highly curated audience of biotech and pharma leaders.
Attendees can connect with:
- Senior decision-makers (Directors, VPs, and C-suite) across genome editing and CRISPR therapeutics
- Experts from companies such as AbbVie, Eli Lilly, Beam Therapeutics, Intellia Therapeutics, Bristol Myers Squibb, and Sanofi
- Specialists in gene editing delivery, clinical development, regulatory strategy, and manufacturing
Networking opportunities are built into the agenda, including:
- Structured networking sessions and speed networking formats
- Interactive roundtables and panel discussions linked to key topics like in vivo delivery and clinical translation
- Dedicated networking breaks and informal discussions throughout the event
- Opportunities to connect directly with speakers and partners following their sessions
With a 80% Director, VP and C-Suite level speaker faculty and audience, this conference provides a focused environment for meaningful, commercially relevant conversations, helping attendees build partnerships and exchange insights that can directly support their genome editing therapeutics strategies.
Yes. The 7th Genome Editing Therapeutics Conference features a world-class speaker faculty made up of senior leaders driving innovation in genome editing therapeutics.
You can expect insights from:
- Ishani Dasgupta, Senior Scientist, AbbVie
- Birgit Schultes, Chief Scientific Officer, Intellia Therapeutics
- Gopi Shanker, Chief Scientific Officer, Beam Therapeutics
- John Moore, Senior Director, Translational Gene Editing, Eli Lilly
- Matthew Laurie, Senior Scientist, Bristol Myers Squibb
- Lalit Kumar Director, Clinical Bioanalytics & Translational Sciences, Beam Therapeutics
- Alan Brooks, Senior Vice President, Research, Metagenomi Therapeutics
- Wei-Chiang Chen, Associate Director, Sanofi
- Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
- Lauren Young Senior Director, Genomics & Computational Biology, Beam Therapeutics
...and more!
Yes. The 7th Genome Editing Therapeutics Summit includes a dedicated scientific poster session showcasing the latest research in genome editing therapeutics.
Attendees benefit from:
- Direct access to cutting-edge research and innovation
- Opportunities to engage with scientists and early-stage biotech teams
- Informal discussions that can lead to collaboration and partnership opportunities
This session complements the main program by providing visibility into emerging science shaping the future of genome editing.
Find out more information about this year’s Genome Editing Poster Session here.
Attendance
Yes. Now is a critical and defining moment for the genome editing therapeutics field, as regulatory momentum, clinical progress, and technological innovation are accelerating together.
Recent FDA signals, including the Plausible Mechanism Framework and new NGS safety guidance, are showing support for advancing CRISPR therapies towards patients.
At the same time, biotech and pharma companies are pushing forward with clinical-stage genome editing programs, creating urgency to solve key challenges:
- In vivo gene editing delivery and targeting
- Off-target safety and genomic integrity
- IND-enabling data and regulatory alignment
- Scalable manufacturing for commercialization
This is exactly what the 7th Genome Editing Therapeutics Summit is built to address.
As the field transitions from promise to reality, attending this dedicated genome editing therapeutics meeting is essential to stay competitive, informed, and aligned with the rapidly evolving industry landscape.
The 7th Genome Editing Therapeutics Summit attracts a highly targeted audience of biotech and pharma professionals actively developing genome editing therapeutics.
This meeting is designed for senior scientists and decision-makers working across:
- Genome editing and gene therapy R&D
- CRISPR, base editing, and prime editing platforms
- In vivo and ex vivo gene editing
- Delivery technologies (viral and non-viral)
- Translational and clinical development
- Regulatory and CMC for gene editing therapeutics
Attending Companies Include:
Partnership Opportunities
Partnering with the 7th Genome Editing Therapeutics Summit provides a highly targeted platform to position your brand at the forefront of the rapidly evolving genome editing therapeutics space. As a partner, you gain direct access to an 80% Director, VP and C-Suite audience of decision-makers from leading biotech and pharma companies such as AbbVie, Eli Lilly, Beam Therapeutics, Intellia Therapeutics, Bristol Myers Squibb, Sanofi and many more.
Through a combination of thought leadership opportunities, exhibition presence, and curated networking, you can showcase your capabilities across key areas such as CRISPR technologies, gene editing delivery, manufacturing, and analytics. With sessions covering in vivo and ex vivo gene editing, clinical translation, and scalable manufacturing, partnering enables you to align your solutions directly with the industry’s most pressing challenges and innovation priorities.
Find out more information about partnership opportunities in the event brochure.
Yes, we have a range of bespoke partnership opportunities available, designed for companies supporting critical needs across genome editing therapeutics, including CRISPR platform development, gene editing delivery (viral and non-viral), lipid nanoparticle (LNP) technologies, off-target analysis, translational biology, and scalable manufacturing.
These tailored packages are built to align with the summit’s core scientific focus, spanning across in vivo and ex vivo gene editing, clinical development, and regulatory strategy to ensure partners can position their solutions directly alongside the most pressing challenges faced by leading biotech and pharma organizations.
Available Inventory Includes:
- Speaking Slots
- Panel Discussion Hosting
- Additional Conference Passes
- Roundtable Hosting
- Full Delegate List
- Exhibiting Booths
- Physical Event Branding
- Sponsored Drinks Reception/Lunches/Breakfasts
- Strategic Seat Drops
- Branded Event Items
If your solutions align with this, get in touch here to discuss how our tailored partnership packages can support your specific strategic and commercial goals.
Yes, partnering provides direct access to a highly curated audience of senior-level professionals actively working in genome editing therapeutics and gene therapy.
The attendee profile includes:
- Directors and VPs of Genome Editing
- Heads of Translational Science and Clinical Development
- Scientific experts in CRISPR, delivery technologies, and CMC
With representation from companies such as Beam, Intellia, AbbVie, Eli Lilly, Bristol Myers Squibb, Metagenomi, Prime Medicine, egenesis, Arbor Biotech and more, partners can engage with individuals who are directly responsible for progressing genome editing pipelines. Through 1:1 meetings, networking sessions, and interactive discussions, partnering facilitates meaningful, business-relevant conversations rather than broad, untargeted exposure.
You can contact us at sponsor@hansonwade.com and a member of the team will get back to you shortly.
Registration
You can register directly through our Registration Page. Please ensure you review the pricing & registration details.
Alternatively, if you have any questions or would like more information on how to register, you can get in touch at info@hansonwade.com and a member of the team will be in contact shortly.
Yes. Discounts ranging from 10% to 20% are available for teams registering two or more attendees from the same organization, making participation more cost effective for cross‑functional R&D groups. Find out more here.
Explore the Agenda
See exactly which delivery, manufacturing and regulatory sessions are relevant to your genome editing program.
Partner With Us
Put your solutions in front of the genome editing decision-makers actively looking for them.
Join Genome Editing Experts
Connect with the R&D, clinical and regulatory leaders driving genome editing therapeutics forward.